Medication Adherence and Glycemic Control among Patients With Type 2 Diabetes Enrolled in a Chronic Disease Management Program in Primary Care Settings

Authors

  • Asep Sukohar Department of Pharmacology and Clinical Pharmacy, Faculty of Medicine, University of Lampung, Bandar Lampung, Indonesia
  • Reimma Emily Rachman Medical Education Program, Faculty of Medicine, University of Lampung, Bandar Lampung, Indonesia
  • Nistita Abighail Medical Education Program, Faculty of Medicine, University of Lampung, Bandar Lampung, Indonesia
  • Septia Eva Lusina Department of Forensic Medicine, Faculty of Medicine, University of Lampung, Bandar Lampung, Indonesia
  • Muhammad Akmal Ghani Faculty of Medicine, University of Lampung, Bandar Lampung, Indonesia

DOI:

https://doi.org/10.51601/ijhp.v6i1.571

Abstract

Medication adherence plays a crucial role in achieving optimal glycemic control in patients with type 2 diabetes mellitus. However, poor glycemic control remains common despite the availability of antidiabetic therapy through the Chronic Disease Management Program (Prolanis), and evidence regarding this association among program participants is still limited. This study aimed to analyze the association between antidiabetic medication adherence and glycemic control based on HbA1c levels in patients with type 2 diabetes mellitus enrolled in Prolanis. An analytical observational study with a cross-sectional design was conducted among 118 Prolanis participants at primary health care facilities in Lampung Province, Indonesia, in 2025 using consecutive sampling. A total of 118 respondents were included in the final analysis, with a mean age of 54.09 ± 10.66 years. Medication adherence was assessed using the Morisky Medication Adherence Scale-8, while glycemic control was evaluated based on HbA1c categories. Data were analyzed using the Chi-square test with a significance level of p < 0.05. The results showed that most respondents had moderate medication adherence (38.1%) and poor glycemic control (50.8%). A significant association was found between medication adherence and glycemic control (p = 0.037; Cramér's V = 0.208), indicating a small-to-moderate effect size. These findings highlight the need to strengthen adherence-focused interventions, including patient education, routine monitoring, and continuous support, as part of Prolanis implementation to improve long-term glycemic outcomes in primary care settings.

Downloads

Download data is not yet available.

References

[1] American Diabetes Association. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. Diabetes Care [Internet]. 2025;48(January):S27–S49. Available from: https://doi.org/10.2337/dc25-S002.

[2] Ajrouche S, Louis L, Esvan M, Chapron A, Garlantezec R, Allory E. HbA1c Changes in a Deprived Population who Followed or not a Diabetes Self-Management Programme, Organised in a Multi-Professional Primary Care Practice: a Historical Cohort Study on 207 Patients between 2017 and 2019. BMC Endocr Disord [Internet]. 2024;24(1):1–11. Available from: https://doi.org/10.1186/s12902-024-01601-9

[3] International Diabetes Federation. International Diabetes Federation Atlas 11th Edition 2025 [Internet]. Diabetes Atlas. 2025. Available from: https://doi.org/10.1111/1753-0407.12644.

[4] Kementerian Kesehatan Republik Indonesia. Survei Kesehatan Indonesia 2023 (SKI). Kementerian Kesehatan Republik Indonesia; 2023.

[5] Dinas Kesehatan Provinsi Lampung. Profil Kesehatan Provinsi Lampung Tahun 2024 Pemerintah Provinsi Lampung Dinas Kesehatan. Bandar Lampung: Dinas Kesehatan Lampung; 2024.

[6] American Diabetes Association. Introduction and Methodology: Standards of Care in Diabetes—2024. Diabetes Care [Internet]. 2024;47(December 2023):S1 S4. Available from: https://doi.org/10.2337/dc24-SINT.

[7] Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017;66(2):241–55.

[8] Gomes MB, Tang F, Chen H, Cid-Ruzafa J, Fenici P, Khunti K, et al. Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study. Front Endocrinol (Lausanne). 2022;13(April):1–9.

[9] Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.

[10] Nascimento T, Andrade A, Pinto E, Cabrita C, Pais S, Puerta R de la. Medication Adherence and Glycemic Control in Older Adults with Type 2 Diabetes: A Cross-Sectional Study in a Community Setting. Diabetology. 2025;6(5):1–15.

[11] Sendekie AK, Netere AK, Kasahun AE, Belachew EA. Medication Adherence and its Impact on Glycemic Control in Type 2 Diabetes Mellitus Patients with Comorbidity: A Multicenter Cross-Sectional Study in Northwest Ethiopia. PLoS One [Internet]. 2022;17(9 September):1–18. Available from: http://dx.doi.org/10.1371/journal.pone.0274971

[12] Zamanillo-Campos R, Zaforteza Dezcallar M, Boronat Moreiro MA, Leiva Rus A, Ripoll Amengual J, Konieczna J, et al. Non-Adherence to Non-Insulin Glucose-Lowering Drugs: Prevalence, Predictors and Impact on Glycemic Control and Insulin Initiation. A Longitudinal Cohort Study in a Large Primary Care Database in Spain. Eur J Gen Pract. 2023;29(1):1–10.

[13] Sahoo J, Mohanty S, Kundu A, Epari V. Medication Adherence Among Patients of Type II Diabetes Mellitus and Its Associated Risk Factors: A Cross-Sectional Study in a Tertiary Care Hospital of Eastern India. Cureus. 2022;14(12):6–14.

[14] Arshed M, Kiran M, Ashraf W, Virk MKS, Qamer S, Umer MF, et al. Non-Adherence to Oral Antidiabetic Medications among Patients with Type 2 Diabetes: Evidence from a Nationwide Multicentre Study in a Lower-Middle-Income Country. BMC Public Health. 2025;25(1).

[15] World Health Organization. WHO Guideline on Self-Care Interventions for Health and Well-Being, 2022 Revision. Geneva: World Health Organization; 2022. 1–186 p.

[16] Badan Penyelenggara Jaminan Sosial. Panduan Praktis Prolanis (Program Pengelolaan Penyakit Kronis). BPJS Kesehatan; 2020.

[17] Li H, Min H, Zhang L, Li Y, Wang J, Jia X. The Relationships between Social Support, Medication Adherence, and Glycemic Control among Inpatients with Type 2 Diabetes: A Cross-Sectional Survey in Xi’an, China. Front Pharmacol. 2025;16(June):1–14.

[18] Hutagalung SC. Implementasi PROLANIS Berbasis Edukasi Komunitas untuk Meningkatkan Manajemen Mandiri Pasien DM dan Hipertensi. RIGGS J Artif Intell Digit Bus. 2025;4(4):2009–14.

[19] Peabody JW, de Belen E, Dahlen JR, Acelajado MC, Tran MT, Paculdo DR. Variation in Diabetes Management: A National Assessment of Primary Care Providers. J Diabetes Sci Technol. 2020;14(1):70–6.

[20] Soraya IA, Sauriasari R, Prawiroharjo P, Risni HW. The Association between Adherence to Oral Antihyperglycemic Agent and HbA1c Level. Pharm Sci Res. 2022;9(2):93–101.

[21] Zairina E, Nugraheni G, Sulistyarini A, Mufarrihah, Setiawan CD, Kripalani S, et al. Factors Related to Barriers and Medication Adherence in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study. J Diabetes Metab Disord. 2022;21(1):219–28.

[22] Sari DR, Wahid RAH, Ambarsari DW. Knowledge and Medication Adherence among Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study in Yogyakarta, Indonesia. Indones J Pharm Educ. 2025;5(3):311–24.

[23] Sarraf DP, Gupta PP. A Hospital‑Based Assessment of Glycemic Control and Medication Adherence in Type 2 Diabetes Mellitus in Eastern Nepal. J Fam Med Prim Care. 2023;6(2):169–70.

[24] Suprapti B, Izzah Z, Anjani AG, Andarsari MR, Nilamsari WP, Nugroho CW. Prevalence of Medication Adherence and Glycemic Control among Patients with Type 2 Diabetes and Influencing Factors: A Cross-Sectional Study. Glob Epidemiol [Internet]. 2023;5(March):100113. Available from: https://doi.org/10.1016/j.gloepi.2023.100113

[25]. Abdelhamid ZG, Abdel-Salam DM, Mohamed GA, El-Megeed HSA. Medication Adherence and Illness Perception among Diabetic Patients in Upper Egypt. BMC Endocr Disord. 2025;25(1).

[26] Highton PJ, Funnell MP, Gupta P, Zaccardi F, Lim LL, Seidu S, et al. Improving Medication Adherence in Type 2 Diabetes: Strategies for Better Clinical and Economic Outcomes. Diabetologia [Internet]. 2025;69(3):541–56. Available from: https://doi.org/10.1007/s00125-025-06617-x

[27] Chin SS, Lau SW, Lim PL, Wong CM, Ujang N. Medication Adherence, its Associated Factors and Implication on Glycaemic Control in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study in a Malaysian Primary Care Clinic. Malaysian Fam Physician. 2023;18:1–11.

[28] Kwakye AO, Kretchy IA, Peprah P, Mensah KB. Factors Influencing Medication Adherence in Co-morbid Hypertension and Diabetes Patients: A Scoping Review. Explor Res Clin Soc Pharm [Internet]. 2024;13(December 2023):100426. Available from: https://doi.org/10.1016/j.rcsop.2024.100426

[29] Shaikh N, Qureshi N, Qureshi MJ, Mian ZR, Saeed H, Rana MA, et al. Association of Antidiabetic Medication Regimens and Medication Adherence With HbA1c Reduction in Type 2 Diabetic Patients: A Retrospective Study. Cureus. 2025;17(9):1–9.

[30] Vázquez LA, Romera I, Rubio-de Santos M, Escalada J. Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes. Diabetes Ther. 2023;14(11):1771–84.

[31] Eliza D, Syafhan NF, Andrajati R, Fitriani SW. Medication Adherence, Glycemic Control and Quality of Life in Patients with Type 2 Diabetes Mellitus: a cross-sectional study. J Sains Farm Klin. 2023;10(1):21.

[32] Hilyah D, Kuswinarti, Ramadhanti J. Family Support in Adherence to Oral Anti-Diabetic Medications among Patients with Type 2 Diabetes Mellitus. Althea Med J. 2025;12(1):22–7.

[33] Shahin W, Kennedy GA, Stupans I. The Impact of Personal and Cultural Beliefs on Medication Adherence of Patients with Chronic Illnesses: A Systematic Review. Patient Prefer Adherence. 2019;13:1019–35.

[34] Guo Z, He Z, Li H, Zheng L, Shi L, Guan X. Effect of the Full Coverage Policy of Essential Medicines on Medication Adherence: A Quasi-Experimental Study in Taizhou, China. Front Public Heal. 2022;10.

[35] Shin G, Jang B, Bae G, Jeon HL, Bae SJ. The Impact of Payment Scheme Changes on Medication Adherence and Persistence of Patients Diagnosed with Depression in Korea. Int J Environ Res Public Health. 2022;19(17).

[36] Hakami AM, Almutairi B, Alanazi AS, Alzahrani MA. Effect of Mobile Apps on Medication Adherence of Type 2 Diabetes Mellitus: A Systematic Review of Recent Studies. Cureus. 2024;16(1):1–8.

[37] Spanakis M, Fournaraki A, Nimee F, Kontogiorgis C, Symvoulakis EK. Bridging Innovation and Practice in Type 2 Diabetes Mellitus : Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists. Pharmaceuticals. 2026;(Dm):1–24.

[38] Figueiredo RG, Patino CM, Ferreira JC. Cross-Sectional Studies: Understanding Applications, Methodological Issues, and Valuable. Bras Pneumol. 2025;51(1):e20250047.

Downloads

Published

2026-03-01

How to Cite

Sukohar, A., Emily Rachman, R., Abighail, N., Eva Lusina, S., & Akmal Ghani, M. (2026). Medication Adherence and Glycemic Control among Patients With Type 2 Diabetes Enrolled in a Chronic Disease Management Program in Primary Care Settings. International Journal of Health and Pharmaceutical (IJHP), 6(1), 450–458. https://doi.org/10.51601/ijhp.v6i1.571

Issue

Vol. 6 No. 1 (2026): February 2026

Section

Articles

License

Copyright (c) 2026 Asep Sukohar, Reimma Emily Rachman, Nistita Abighail, Septia Eva Lusina, Muhammad Akmal Ghani

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.